Lupin launches Ranibizumab biosimilar in Europe via Sandoz
In short
Lupin launched its Ranibizumab biosimilar in Europe through Sandoz, except in Germany. The European Commission had approved Ranluspec in vial and pre-filled syringe forms for retinal disease treatment.
It also gives doctors and patients more treatment formats.
What the reporting says
Lupin launched its biosimilar Ranibizumab through Sandoz in Europe except Germany, after Ranluspec was approved by the European Commission in vial and pre-filled syringe forms for retinal disease treatment. The approval covers two presentation formats, according to the BusinessLine Companies summary. The move expands access to the medicine in the covered European markets.
Why it matters
Lupin launched its biosimilar Ranibizumab through Sandoz across Europe except Germany, following European Commission approval of Ranluspec in vial and pre-filled syringe forms for retinal disease treatment. The move is relevant to Lupin, Sandoz and European healthcare markets. It may broaden commercial access to the biosimilar in the approved regions.